Arthneeti

Nectar Lifescience Share Price & Earnings Call Analysis

₹10.14-0.39% today
Market cap
₹197 Cr
ROE
-31.28%
Price to sales
80.73
Debt to equity
0.00
52W high / low
₹22.2 / ₹9.30
EBITDA margin
-3520.08%
Net profit margin
-2853.23%
Promoter holding
51.84%
Sales (last year)
₹2 Cr

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Nectar Lifescience rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹17,925 Cr—
440%+Flat₹5,223 Cr39.1
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Sign up free to see every company in the sector ranking and track Nectar Lifescience.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Nectar Lifescience

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Nectar Lifescience

Quarterly Results

Quarter-by-quarter operating performance

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales +34438939439845244135960431510
Expenses +34337135937141039331960585602
Operating Profit1183627424840-1-0-154-11-2
OPM %0%5%9%7%9%11%11%-10%-500%-36%-16%77%
Other Income +1318011011780-62-17635
Interest1720182125242000180030
Depreciation151515151515150016100
Profit before tax-18232211558-188-64-1763
Tax %-47%-145%41%38%36%95%40%-2%2%-31%-1%0%-339%
Net Profit +-942121368-130-63-17614
EPS in Rs-0.410.160.080.050.070.030.130.250.35-5.80-2.82-7.850.64

Financials of Nectar Lifescience

Profit & Loss

Annual income statement trend

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales +1,6341,6381,6741,6351,8742,7792,3631,5411,6651,5201,6821,664437
Expenses +1,3451,3711,4361,4111,6382,5142,1431,4321,5071,4671,5301,694593
Operating Profit28926723922423626422010915953152-30-157
OPM %18%16%14%14%13%10%9%7%10%3%9%-2%-36%
Other Income +1220623664-221143155-203
Interest1381261231171151481261127979877548
Depreciation84775762646361605759616216
Profit before tax78856467635937-8534-4218-162-424
Tax %21%22%15%18%17%19%15%-14%26%-43%73%-30%
Net Profit +62665455524832-7325-245-114-355
EPS in Rs2.772.952.422.472.332.121.42-3.271.12-1.080.22-5.07-15.83
Dividend Payout %4%3%4%2%2%2%4%0%0%0%0%0%

Financials of Nectar Lifescience

Balance Sheet

Capital structure and asset base

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital22222222222222222222222222
Reserves9059369329841,0361,0831,1141,0401,0651,0421,047934694
Borrowings +858925962878955903779903860754636582459
Other Liabilities +609628640696710696718423443371486509639
Total Liabilities2,3942,5102,5562,5812,7242,7052,6332,3882,3912,1892,1912,0471,815
Fixed Assets +94893490688185282578577272366264363328
CWIP122919910210010011599857866570
Investments0111110111111
Other Assets +1,3241,4851,5511,5971,7711,7801,7331,5171,5821,4491,4821,3571,786
Total Assets2,3942,5102,5562,5812,7242,7052,6332,3882,3912,1892,1912,0471,815

Financials of Nectar Lifescience

Cash Flows

Operating, investing and financing cash movement

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +255144169199652392852195134225169
Cash from Investing Activity +-90-60-77-18-29-26-33-291752-17-42
Cash from Financing Activity +-161-61-89-204-40-201-25211-119-186-205-128
Net Cash Flow4233-23-412-04-8-02-1
Free Cash Flow153648717432204249-10110183195126
CFO/OP95%56%74%92%33%96%134%23%60%252%148%-574%

Financials of Nectar Lifescience

Ratios

Working capital efficiency and return ratios

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days849910711211973618998678276
Inventory Days240253260270226151192185197212215184
Days Payable13914615416714280104108112100127117
Cash Conversion Cycle185207213215203145150166182179170143
Working Capital Days23404145674653673776343
ROCE %12%11%10%10%9%10%8%3%5%-0%6%-5%

Continue your research

Others in Pharmaceuticals & Biotechnology this season

  • Anthem Bioscienc (Q2 FY27)

    Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc

  • Neuland Laboratories (Q2 FY27)

    Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q

  • Hikal (Q2 FY27)

    Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest

  • Kopran (Q2 FY27)

    9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals